The document summarizes Ind-Swift Laboratories Limited, a pharmaceutical group based in India. Some key points: - It was founded in 1986 and has grown to a consolidated turnover of around Rs. 2200 Crores with businesses in APIs, chemicals, infrastructure, education, and media. - It is a leading research-driven pharmaceutical group operating in over 56 countries and catering to regulators like USFDA, MHRA, and others. - The group has manufacturing facilities in India and wholly owned subsidiaries in the US, UK, Iran, Dubai, and Singapore. - It manufactures over 40 API products across 16 therapeutic categories and has international approvals from regulators in the US,

2. IND-SWIFT LABORATORIES LIMITED
Akash Deep Sharma
Asst Manager- Corporate HR

3. • Swift is the fastest flying bird on earth. It is the
philosophy behind the genesis of the name Ind-
Swift, Incepted in 1986 when three visionaries
the Mehtas, the Munjals and the Jains, all 1st
generation entrepreneurs visualized the business
• Today with strong business acumen, apart from
pharmaceutical business Ind-swift has also
progressively forayed in diversification into
multifarious fields viz API, Chemicals,
Infrastructure, Printing & Packaging Stationary,
Education and Media Publication with its every
unit as an independent profit earning centre

5. Ind-Swift Laboratories Limited
Registered Office : SCO 850, Shivalik Enclave, Manimajra
Chandigarh (INDIA) | www.indswiftlabs.com
NSE : INDSWFTLAB BSE : 532305 REUTERS : ISLB.BO BLOOMBERG : ISL@IN
• Ind-Swift group’s holds consolidated turnover of
around Rs. 2200 Crores
• Ranked among 500 Fortune Companies in 2013
• We have presence in more than 56 countries
across the globe.
• We are one of leading research driven
pharmacutical groups operating in the region and
catering the needs of USFDA, MHRA & ROW
Markets
• We have wholly owned subsidiaries in US, UK,
Iran, Dubai and Singapore

6. Ind-Swift
Group
Ind-Swift
Laboratories
Limited
(API)
Ind-Swift
Limited
(Finished Dosage)
Derabassi (Punjab)
Samba ( Jammu & Kashmir )
Jawaharpur (Punjab)
Panchkula (Haryana)
Parwanoo (Himachal Pradesh)
Samba ( Jammu & Kashmir )
Baddi (Himachal Pradesh)

7. ISLL
ISL

9. 9
1995
Incorporated by Ind Swift
Limited with PSIDC
1998
IPO for Rs. 75 Mn
raised
‘97
2006
USD 10 mn
GDR raised
2007
2010
‘95 ‘10
2004
 Maiden dividend
 Sets up subsidiary in
US
 Launched Nitazoxanide
in Asia for the first time
First Plant at Derabassi
commences production
2005
Second Plant at
Jammu
established
 New R&D facility in Mohali.
 JV in Iran to manufacture
APIs
USFDA
approval for
Clarithromycin
KFDA approval
for one product
Ventured into
Phyto-Chemicals
biz
2008
1997

11. Ind Swift
Laboratories
Incorporated (USA)
Wholly owned subsidiary -
represents the activities of Ind
Swift Labs in North America
(USA & Canada) & Latin
America.
Ind Swift Middle
East FZE
(Dubai)
Established to help
company reach out to the
Middle East & African
markets.
Ind Swift Laboratories Limited
Meteoric Life
Sciences Pte. Limited
(Singapore)
Recently established subsidiary to
help company expand its base
across South East Asia.
Marketing Offices
Offices in HangZhou (China) &
London (UK)

12. Positioning of IND-SWIFT LABORATORIES
Amongst Larger API & Phytochemicals Manufacturers in
INDIA
• Manufactures APIs for 10 of the top 25 blockbuster drugs with a
global market ~ US$ 35 billion.
• Strong portfolio of 40+ products across 16 therapeutic categories.
• Leading manufacturer of Quality Menthol & Mint Derivatives with a
strong presence in Asia & Europe.
• Worldwide presence in over 50 markets including mature markets
(US, European Union and Japan) and “pharmerging” markets.
• Amongst largest global manufacturers of Clarithromycin (including
granules).
• API Facilities approved by USFDA , MHRA, TGA & KFDA.

13. 13
Composition of IND-SWIFT Laboratories
R&D Income
1.1%
Other APIs /
intermediates
56.6%
Clarithromycin
19.2%
Fexofenadine
4.4%
Clopidogrel
8.4%
Mint
Deravatives
8.7%
Atorvastatin
1.7%
Global presence , Asia & Europe are key markets.
Diversified product mix ,
Clarithromycin is the major revenue
contributor

14. Therapeutic Segments
Segment Product
Macrolide Antibiotics Clarithromycin
Cardiovascular Atorvastatin, Clopidogrel
Anti-Histamine Fexofenadine
Anti-Diabetic Pioglitazone
Anti-Diarrheal Nitazoxanide
Aromatase Inhibitors Letrozole, Anastrozole
Anti-Depressants Venlafaxine
Anti-Psychotic Quetiapine, Aripiprazole
Alzheimer Disease Donepezil
Anti-Migrane Naratriptan
Anti-Cancer Imatinib , Temozolamide
Bone Resorption Inhibitor Risedronate Sodium
Parkinson Disease Ropinirole HCl
Hyperparathyoidism Cinacalcet
Antihypertensive Telmisartan, Olmesartan Medoxomil
Alcohol Abstinence Acamprosate Calcium
Over 40 Products Across 16 Segments

15. API Manufacturing
20 cGMP compliant
Manufacturing blocks spread
over two locations.
• One facility each in Derabassi and
Jammu
• Reactor capacity 480 KL with over
650,000 sq ft area.
• Capacity : 590 MT for bulk drugs, 3600
MT for mint derivatives
Derabassi
• Spread over 37 acres.
• USFDA / TGA / MHRA approved facility.
• Containment facility catering to high
potency drugs.
• 11 facilities for regulated markets.
Facility At Derabassi
• 8 acre facility.
• Catering to domestic / unregulated
markets.
• Products include atorvastatin, clopidogrel
bi sulphate & nitazoxanide.
Jammu Facility At Jammu

16. ISLL – in Pictures
R&D Centre (at Mohali, Punjab)

17. 17
Research and Development
• Annual spend ~ 9% of net revenue.
• Dedicated R&D center at Mohali with around 100
scientists.
• Strong capabilities to develop non - infringing APIs
requiring complex chemistry and multiple reactions.
151 Patent
Filings
302 DMFs
Products in 16
Therapeutic Segments
R&D Center : Mohali
Focus Area
Corporate Presentation |
Private & Confidential
Figures in INR Millions

18. MANUFACTURING FACILITY
AREA CLASSIFICATION
Increasing GMP requirement
General
(uncontrolled)
Level-I
(General)
Level-II
(protected)
Level-III
(Controlled)
Electrical panel
room, toilets,
change room
Intermediate
production area
Isolation and
purification of API
Powder processing,
drying, packaging,
change room,
Quarantine
Natural air
ventilation
Min 15 air changes
per hour
Min 20 air changes
per hour
Min. 30 air changes
per hour
Ambient
temperature
Ambient
temperature
Air of <30 0
C is
supplied (with once
through system)
23±20
C
Relative humidity
<60%

19. INTERNATIONAL APPROVALS
Year Country/Authorities Product
2004 Ministry of Health, Iran Clarithromycin, Atorvastatin Calcium,
Clarithromycin Granules
2006 Therapeutic Goods Administration (TGA),
Australia
Clarithromycin
2007 United State Food & Drug Administration
(USFDA), US
Clarithromycin
2007 National Institute of Pharmacy (NIP), Hungary Anastrozole
2008 German Health Authority, Behorde fur Soziales,
Familie, Gesundheit und Verbraucherschutz,
Germany
Atorvastatin Calcium, Clopidogrel
Besylate, Aripiprazole
2010 Korean Food & Drug Administration (KFDA),
Korea
Risedronate Sodium, Ezetimibe
2010 Pharmaceutical and Medical Devices
Agency (PMDA), Japan
Risedronate Sodium, Pioglitazone
Hydrochloride

20. INTERNATIONAL APPROVALS
Year Country/Authorities Product
2011 Therapeutic Goods Administration
(TGA), Australia
Clarithromycin, Donepezil Hydrochloride,
Letrozole, Ropinirole Hydrochloride,
Acamprosate Calcium, Aripiprazole,
Pioglitazone Hydrochloride
2011 National Organization of Medicine
(NOM), Greece
Clarithromycin, Clarithromycin
Granules
2011 German Health Authority, Behorde
fur Gesundheit und Verbraucherschutz,
Germany
Atorvastatin Calcium, Aripiprazole
2011 United State Food & Drug
Administration (USFDA), US
Clarithromycin, Donepezil
Hydrochloride, Acamprosate
calcium, Ropinirole Hydrochloride,
Naratriptan Hydrochloride
2012 Pharmaceutical and Medical Devices
Agency (PMDA), Japan
Clarithromycin
2012 PharmAssess Rephine Ltd., UK Site GMP Compliance

21. INTERNATIONAL APPROVALS
Year Country/Authorities Product
2006 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Clarithromycin
2009 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Clarithromycin Special
2009 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Fexofenadine Hydrochloride
2010 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Letrozole
2011 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Acamprosate Calcium
2013 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Telmisartan
2013 European Directorate for the Quality of Medicines &
HealthCare (EDQM), France
Atorvastatin Calcium Trihydrate

22. NATIONAL APPROVALS
Year Country/Authorities Product
2003-2012 WHO GMP, India Clarithromycin Citrate, Clopidogrel Besylaet, Ezetimibe,
Naratriptan Hydrochloride, Nateglinide, Pioglitazone
Hydrochloride, Quetiapine Fumarate, Risedronate Sodium,
Ropinirole Hydrochloride, Clopidogrel Bisulphate,
Acamprosate Calcium, Aripiprazole, Donepezil Hydrochloride,
Atorvastatin Calcium, Fexofenadine Hydrochloride,
Clarithromycin Granules, Clarithromycin, Anastrozole,
Cinacalcet Hydrochloride, Ivabradine Hydrochloride,
Letrozole, Naratriptan Hydrochloride, Nateglinide,
Telmisartan, Menthol
2003 ISO 9001:2000
(Upgraded w.r.t. ISO
9001:2008)
For overall quality management system

23. • We are Hiring B Tech Chemical Engineers
for our API division
• Selection Process-SP
• Offer - Offer

24. Wishing You A Very Good Luck !!